dr. jonasch on the potential of immunotherapy for sarcomatoid rcc
Published 7 years ago • 195 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:04
dr. jonasch on first- and second-line options for patients with rcc
-
1:19
dr. clark on the potential of immunotherapy in renal cell carcinoma
-
1:04
dr jonasch on the preliminary efficacy of nkt-2152 in advanced ccrcc
-
1:04
dr. jonasch on modulating the tumor microenvironment in rcc
-
1:10
dr. jonasch on molecular understanding of clear cell rcc
-
0:57
dr. jonasch on sequencing challenges in rcc
-
0:54
dr. jonasch on promise of immuno-oncology agents in rcc
-
1:11
dr. motzer on the milestone of immunotherapy in rcc
-
0:27
eric jonasch, md, on integrating immunotherapies into renal cell carcinoma treatment algorithms
-
1:40
dr. jonasch on using the tumor microenvironment and epigenetics as biomarkers in rcc
-
1:17
dr. hammers on the future of immunotherapy in rcc
-
1:52
dr. powles on monitoring immunotherapy effects in patients with rcc
-
1:52
dr. choueiri on using immunotherapy to treat rcc
-
1:05
dr. pal on potential tivozanib-based combinations in rcc
-
2:17
dr. chowdhury on pembrolizumab plus pazopanib in rcc
-
1:02
dr. choueiri on the research with immunotherapy in rcc
-
2:25
dr. tykodi on the keynote-427 trial with pembrolizumab in rcc
-
5:49
importance of risk assessment in renal cell carcinoma